Related Experiment Video
Updated: May 12, 2026
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy
Kiran Shivaraj1, Omar Mamlouk1, Amanda Tchakarov2
1Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chimeric antigen receptor (CAR) T-cell therapy can cause kidney injury. A rare case of minimal change disease and nephrotic syndrome after CAR T-cell therapy highlights potential podocyte toxicity and the need for further research.
Area of Science:
- Nephrology
- Oncology
- Immunology
Background:
- Acute kidney injury (AKI) is a known complication of chimeric antigen receptor (CAR) T-cell therapy.
- Glomerular diseases are rare complications of CAR T-cell therapy.
- B-cell maturation antigen (BCMA)-directed CAR T-cell therapy is used for relapsed refractory multiple myeloma.
More Related Videos
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
